Compare Summit Therapeutics Inc (SMMT) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Summit Therapeutics Inc trades at $14.01 (market cap $12.06B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $30.91. Which is the better fit depends on your goals.
| SMMT | TMF | |
|---|---|---|
Market Cap | $12.06B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $26.98 | $44.14 |
52-Week Low | $12.55 | $30.59 |
Enterprise Value | $11.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.10, showing minimal daily change. The technical outlook is bullish based on moving averages, though the stock faces critical FDA review for its lead drug ivonescimab by November 2026. Recent news includes regulatory approval in China and expanded clinical trials, but the company reports significant losses and negative cash flow from operations, highlighting its pre-revenue biotech status.
The investment case hinges on ivonescimab's regulatory success, with a consensus price target of $24.18 implying substantial upside. However, high execution risk, ongoing losses, and a shareholder investigation present significant challenges. The stock offers high-risk, high-reward potential for speculative investors banking on positive clinical and regulatory outcomes.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $30.72, down 0.29% on the day, with a bearish technical signal driven by moving averages. The leveraged ETF structure amplifies daily returns of long-term Treasuries, making it highly sensitive to interest rate movements. Recent news highlights significant long-term value erosion, with a $10,000 investment five years ago now worth approximately $1,527, underscoring the risks of daily rebalancing in volatile markets.
Outlook remains speculative with high risk; potential exists if long-term Treasury yields decline, but the leveraged decay and bearish technicals suggest caution. Investors should consider TMF only for short-term tactical plays, not long-term holdings, due to structural erosion and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
